Last $6.27 USD
Change Today -0.08 / -1.26%
Volume 22.3K
CBRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 2:19 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

columbia laboratories inc (CBRX) Snapshot

Open
$6.29
Previous Close
$6.35
Day High
$6.39
Day Low
$6.18
52 Week High
09/9/13 - $8.37
52 Week Low
07/30/13 - $5.20
Market Cap
67.5M
Average Volume 10 Days
41.4K
EPS TTM
$0.34
Shares Outstanding
10.8M
EX-Date
--
P/E TM
18.2x
Dividend
$1.00
Dividend Yield
--
Current Stock Chart for COLUMBIA LABORATORIES INC (CBRX)

Related News

No related news articles were found.

columbia laboratories inc (CBRX) Related Businessweek News

No Related Businessweek News Found

columbia laboratories inc (CBRX) Details

Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and analytical and consulting services to the pharmaceutical industry. It focuses on the sale of CRINONE, a progesterone gel to its marketing partner. The company has licensed CRINONE to Merck Serono S.A. outside the United States; and has sold the rights to CRINONE to Actavis, Inc. in the United States. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

77 Employees
Last Reported Date: 03/5/14
Founded in 1986

columbia laboratories inc (CBRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $271.1K
Director and Chief Executive Officer of Molec...
Total Annual Compensation: $86.0K
Compensation as of Fiscal Year 2013.

columbia laboratories inc (CBRX) Key Developments

Columbia Laboratories Inc. Hires Charles Maher as Head of U.S. Sales Position

Columbia Laboratories Inc. created a head of U.S. sales position to increase visibility for the company's service offering in the U.S. and drive domestic growth. To fill this new role, the company hired Charles Maher, whose extensive senior commercial experience in the global contract services market should benefit the efforts to capitalize on newly expanded Nottingham facility, manufacturing capabilities and growing suite of enabling technologies.

Columbia Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Fiscal 2014

Columbia Laboratories Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company total net revenues of $7,248,000 against $6,316,000 a year ago. The decrease in revenues primarily reflects the absence of CRINONE (progesterone gel) orders from one of Merck Serono S.A.'s (Merck Serono) higher-volume, higher-margin markets during the first quarter of 2014. Income from operations was $124,000 against $1,013,000 a year ago. Income before income taxes was $441,000 against $1,245,000 a year ago. Net income was $429,000 against $1,242,000 a year ago. Diluted net income per share was $0.01 against $0.09 a year ago. Adjusted EBITDA was $778,000 against $1,910,000 a year ago. Cash flow from operations increased to $900,000 as compared with $700,000 in the first quarter of 2013. The company provided earnings guidance for the fiscal 2014. Based on current market conditions and visibility, the company expects total revenues for fiscal 2014 to increase between 8% to 12%. The company anticipates maintaining positive cash flows from operations going forward.

Columbia Laboratories Inc. to Report Q1, 2014 Results on Apr 29, 2014

Columbia Laboratories Inc. announced that they will report Q1, 2014 results on Apr 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBRX:US $6.27 USD -0.08

CBRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.04 USD +0.15
View Industry Companies
 

Industry Analysis

CBRX

Industry Average

Valuation CBRX Industry Range
Price/Earnings 12.4x
Price/Sales 2.5x
Price/Book 1.7x
Price/Cash Flow 11.6x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLUMBIA LABORATORIES INC, please visit www.columbialabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.